3Daughters, a clinical development company specializing in women’s healthcare, has raised $4.7 million in seed funding. This funding round saw participation from Thairm Bio, Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and other undisclosed investors. The company had previously announced the closing of the first tranche of this round, which exceeded $2 million.
Pioneering Contraceptive Technology
Led by CEO Mary Beth Cicero, 3Daughters focuses on developing innovative healthcare solutions for women. The company’s technology platform leverages principles of physics and geometry to deliver targeted therapies to the uterus. Their flagship product, 3D-001, is a frameless, magnetic, non-hormonal intrauterine device (IUD) designed for long-acting contraception. This IUD conforms to a woman’s body, offering a personalized fit and enhanced comfort.
Integrated Insertion and Retrieval System
The 3D-001 IUD is coupled with the patented Slider™ system, which streamlines the insertion and retrieval processes. This system aims to eliminate the steps typically involved in the insertion process and removes the need for strings, which are traditionally required for removal. This innovation is expected to significantly improve the user experience and convenience of IUDs.
Funding and Future Plans
The seed funds will be used to advance the development of the 3D-001 IUD, with plans to file an Investigational New Drug (IND) application by early 2025. Additionally, 3Daughters has launched a Series A financing round, seeking $15 million to support the first-in-human Phase 1 study of 3D-001, which is anticipated to commence following IND approval in 2025.
The successful seed funding round underscores the potential of 3Daughters’ technology to transform women’s healthcare by providing safer, more effective, and user-friendly contraceptive options.
